Presepsin: A Novel and Potential Diagnostic Biomarker for Sepsis

K V Ramana^1, , Venkata BharatKumar Pinnelli², Sabitha Kandi³, Asha G², Jayashankar CA⁴, Bhanuprakash⁵, Raghavendra DS² and Sanjeev D rao¹

¹Department of Microbiology, Prathima Institute of Medical sciences, Karimnagar, India

²Department of Biochemistry, Vydehi Institute of Medical sciences and Research center, Bengaluru, India

³Department of Biochemistry, Chalmeda Anandarao Institute of Medical sciences, Karimnagar, India

⁴Department of General Medicine, Vydehi Institute of Medical sciences and Research center, Bengaluru, India

⁵Department of Dermatology, Vydehi Institute of Medical sciences and Research center, Bengaluru, India

Cite this paper

K V Ramana, Venkata BharatKumar Pinnelli, Sabitha Kandi, Asha G, Jayashankar CA, Bhanuprakash, Raghavendra DS and Sanjeev D rao. Presepsin: A Novel and Potential Diagnostic Biomarker for Sepsis. American Journal of Medical and Biological Research. 2014; 2(4):97-100. doi: 10.12691/AJMBR-2-4-3

Abstract

Sepsis is a potential clinical condition which is a consequence of infectious disease or a severe inflammatory reaction secondary to infection or injury. Sepsis in Greek means putrefaction or decay, correlating well with the multiple organ failure and severe shock resulting in death of the patient suffering from severe sepsis. Clinical management of sepsis requires prompt laboratory diagnosis and formulation of effective patient management strategies that may include antimicrobial chemotherapy in case of sepsis induced by infectious microbe. Although many laboratory biomarkers are available for the diagnosis of sepsis, only few markers have proven to be beneficial in differentiating infectious disease sepsis and sepsis of non-infectious origin. Of the available markers only few have prognostic value. We in this review discuss the utility of a novel and emerging sepsis marker, the presepsin which has a better diagnostic and prognostic value, and has been effective in predicting the survival of the sepsis patients.

Keywords

presepsin, sepsis marker, management of sepsis

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008; 34: 17-60.global death.
[2]	Dupuy, F. Philippart, Y. Pean et al., “Role of biomarkers in the management of antibiotic therapy: an expert panel review. I: currently available biomarkers for clinical use in acute infections,” Annals of Intensive Care, vol. 3, no. 22, article 1, 2013.
[3]	Wu HP, Chen CK, Chung K, Jiang BY, Yu TJ, Chuang DY. Plasma transforming growth factor-b1 level in patients with severe community-acquired pneumonia and association with disease severity. J Formos Med Assoc 2009; 108: 20-27.
[4]	Guignant C, Voirin N, Venet F, Poitevin F, Malcus C, Bohé J, et al. Assessment of pro-vasopressin and pro-adrenomedullin as predictors of 28-day mortality in septic shock patients. Intensive Care Med 2009; 35: 1859-1867.
[5]	J. P. Hinson, S. Kapas, and D. M. Smith, “Adrenomedullin, a multifunctional regulatory peptide, “Endocrine Reviews, vol. 21, no. 2, pp. 138-167, 2000.
[6]	Seligman R, Papassotiriou J, Morgenthaler NG, Meisner M, Teixeira PJ. Prognostic value of midregional pro-atrial natriuretic peptide in ventilator-associated pneumonia. Intensive Care Med 2008; 34: 2084-2091.
[7]	Y. Wu, F. Wang, X. Fan et al., “Accuracy of plasma sTREM-1 for sepsis diagnosis in systemic inflammatory patients: a systematic review and meta-analysis,” Critical Care, vol. 16, no. 6, article R229, 2012.
[8]	Y. Backes, K. van der Sluijs, D. Mackie et al., “Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review Intensive,” Care Medicine, vol. 38, no. 9, pp. 1418-1428, 2012.
[9]	N. Hofer, E. Zacharias, W. Müller, and B. Resch, “An update on the use of C-reactive protein in early-onset neonatal sepsis: current insights and new tasks,” Neonatology, vol. 102, no. 1, pp. 25-36, 2012.
[10]	Longo Dan. Harrison's principles of internal medicine. New York: McGraw-Hill, 2011: 271 millions death.
[11]	Qi Zou, Wei Wen, Xin-chao Zhang. Presepsin as a novel sepsis biomarker. World J Emerg Med 2014; 5 (1): 16-19.
[12]	Cesar Henriquez-Camacho and Juan Losa, “Biomarkers for Sepsis,” BioMed Research International, vol. 2014, Article ID 547818, 6 pages, 2014.
[13]	D. W. Bates, K. Sands, E. Miller et al., “Predicting bacteremia in patients with sepsis syndrome. Academic Medical Center Consortium Sepsis Project Working Group,” Journal of Infectious Diseases, vol. 176, no. 6, pp. 1538-1551, 1997.
[14]	P. Hausfater. Biomarkers and infection in the emergency unit. Médecine et Maladies Infectieuses Volume 44, Issue 4, April 2014, Pages 139-145.
[15]	Elisa Pizzolato, Marco Ulla, Claudia Galluzzo, Manuela Lucchiari. Tilde Manetta, Enrico Lupia et al. Role of presepsin for the evaluation of sepsis in the emergency department. Clinical Chemistry and Laboratory Medicine (CCLM). Volume 0, Issue 0, ISSN (Online) 1437-4331.
[16]	Ulla et al.: Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective study. Critical Care 2013 17: R168.
[17]	Mussap M, Noto A, Fravega M, Fanos V: Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis: new clinical and analytical perspectives for two old biomarkers. J Matern Fetal Neonatal Med 2011, 24(Suppl 2): 12-14.
[18]	Mussap M, Puxeddu E, Burrai P, Noto A, Cibecchini F, Testa M, Puddu M, Ottonello G, Dessì A, Irmesi R, Gassa ED, Fanni C, Fanos V: Soluble CD14 subtype (sCD14-ST) presepsin in critically ill preterm newborns: preliminary reference ranges. J Matern Fetal Neonatal Med 2012, 25(Suppl 5):51-53.
[19]	Palmiere C, Mussap M, Bardy D, Cibecchini F, Mangin P: Diagnostic value of soluble CD14 subtype (sCD14-ST) presepsin for the postmortem diagnosis of sepsis-related fatalities. Int J Legal Med 2013, 127:799-808.
[20]	Masson et al.: Presepsin (soluble CD14subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian outcome sepsis trial. Critical Care 2014; 18: R6.
[21]	Valeria Sargentini, Giancarlo Ceccarelli, Mariadomenica D’Alessandro, Daniela Collepardo, Andrea Morelli, Annalia D’Egidio et al. Presepsin as a potential marker for bacterial infection relapse in critical care patients. A preliminary study. Clinical Chemistry and Laboratory Medicine (CCLM). Volume 0, Issue 0, ISSN (Online) 1437-4331.
[22]	Luis García de Guadiana Romualdo, Patricia Esteban Torrella, Monserrat Viqueira González, Roberto Jiménez Sánchez, Ana Hernando Holgado, Alejandro Ortín Freire et al. Diagnostic accuracy of presepsin (soluble CD14 subtype) for prediction of bacteremia in patients with systemic inflammatory response syndrome in the Emergency Department. Clinical Biochemistry Volume 47, Issues 7-8, May 2014, Pages 505-508.
[23]	Endo S, Suzuki Y, Takahashi G, Shozushima T, Ishikura H, Murai A et al. U sefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J Infect Chemother. 2012 Dec; 18(6): 891-7.
[24]	Filippo Mearelli et al. Procalcitonin, presepsin, pro-adrenomedullin, fibrin degradation products, and lactate in early diagnosis and prognosis of septic patients newly admitted to the intermediate care unit from the emergency department. Critical Care 2013, 17(Suppl 4):P17.
[25]	Tatjana Vodnik, Goran Kaljevic, Tanja Tadic, Nada Majkic-Singh. Presepsin (sCD14-ST) in preoperative diagnosis of abdominal sepsis. Clinical Chemistry and Laboratory Medicine. Volume 51, Issue 10, Pages 2053-2062.
[26]	Özlem Çakır Madenci, Sezer Yakupoğlu, Nur Benzonana, Nihal Yücel, Derya Akbaba, Asuman Orçun Kaptanağası. Evaluation of soluble CD14 subtype (presepsin) in burn sepsis. Burns Volume 40, Issue 4, June 2014, Pages 664-669.
[27]	Oh Joo Kweon, Jee-Hye Choi, Sang Kil Park, Ae Ja Park. Usefulness of presepsin (sCD14 subtype) measurements as a new marker for the diagnosis and prediction of disease severity of sepsis in the Korean population. Journal of Critical Care Available online 21 June 2014.
[28]	Shigeatsu Endo, Yasushi Suzuki, Gaku Takahashi, Tatsuyori Shozushima, Hiroyasu Ishikura, Akira Murai. Presepsin as a powerful monitoring tool for the prognosis and treatment of sepsis: A multicenter prospective study. Journal of Infection and Chemotherapy Volume 20, Issue 1, January 2014, Pages 30-34.
[29]	Novelli, G, Morabito, V, Ferretti, G., Pugliese, F, Ruberto, F, Rossi, M et al. PATHFAST Presepsin assay for early diagnosis of bacterial infections in surgical patients. Preliminary study.: 423 Transplantation: 27 November 2012 - Volume 94 - Issue 10S - p 532.